MG132-mediated inhibition of the ubiquitin–proteasome pathway ameliorates cancer cachexia

The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells

(2012) Eun-Sil Sung et al.   EXPERIMENTAL CELL RESEARCH

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

(2012) Alfeu Zanotto-Filho et al.   INVESTIGATIONAL NEW DRUGS

Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain

(2012) Martha Schneider et al.   JOURNAL OF VIROLOGY

The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis

(2012) Erin M. O'Leary et al.   MOLECULAR GENETICS AND METABOLISM

MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1 pathway

(2011) Yuedong Ma et al.   BIOCHEMICAL PHARMACOLOGY

The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice

(2011) Annabelle Z Caron et al.   BMC MUSCULOSKELETAL DISORDERS

Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia

(2011) Hang Wang et al.   CANCER LETTERS

MG132 Alleviates Liver Injury Induced by Intestinal Ischemia/Reperfusion in Rats: Involvement of the AhR and NFκB Pathways

(2011) Huirong Jing et al.   JOURNAL OF SURGICAL RESEARCH

Definition and classification of cancer cachexia: an international consensus

(2011) Kenneth Fearon et al.   LANCET ONCOLOGY

Prevention of muscle disuse atrophy by MG132 proteasome inhibitor

(2011) Cecile Jamart et al.   MUSCLE & NERVE

Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukaemic cells U937 and the induction of low levels of intracellular superoxide anion

(2011) Tomás Lombardo et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Comparative Study of the Influence of Proteasome Inhibitor MG132 and Ganciclovir on the Cytomegalovirus-Specific CD8+ T-Cell Immune Response

(2011) Yanjun Wang et al.   VIRAL IMMUNOLOGY

Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies

(2010) Shontelle Dodson et al.   Annual Review of Medicine

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

(2010) Xiaolan Zhou et al.   CELL

Signaling pathways perturbing muscle mass

(2010) David J Glass   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Interleukin 6 as a Key Regulator of Muscle Mass during Cachexia

(2010) James A. Carson et al.   EXERCISE AND SPORT SCIENCES REVIEWS

The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease

(2009) S. Inoue et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Mechanisms of Cancer Cachexia

(2009) Michael J. Tisdale   PHYSIOLOGICAL REVIEWS

Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia

(2008) J Faber et al.   BRITISH JOURNAL OF CANCER

Cancer cachexia: Developing multimodal therapy for a multidimensional problem

(2008) K.C.H. Fearon   EUROPEAN JOURNAL OF CANCER

Induction of MuRF1 Is Essential for TNF-α-Induced Loss of Muscle Function in Mice

(2008) Volker Adams et al.   JOURNAL OF MOLECULAR BIOLOGY

Nuclear factor-kappa B signaling in skeletal muscle atrophy

(2008) Hong Li et al.   JOURNAL OF MOLECULAR MEDICINE-JMM